EA5182 - Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

NCT#:

NCT04181060

NCT QR Code

Title:

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Protocol:

EA5182

Cancer Type:

Lung

Study Sponsor:

NCI / ECOG-ACRIN

Brief Summary:

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Study Type:

Interventional

Date Opened at SVH:

2-Sep-2021

Recruitment Status:

Recruiting

Study Population:

Eligibility Criteria:

See SCHEMA

Principal Investigator:

Hong Zhao, MD, Oncology, SVMC Cancer Care, (831) 755-1701

Participating Institution: